UnitedHealthcare Deal: Recent chatter on X about Plus Therapeutics (PSTV) has been fueled by the company’s national coverage agreement with UnitedHealthcare for its CNSide cancer diagnostic test. Many are buzzing about the potential reach to over 51 million individuals, seeing it as a significant step for the company’s growth in the biotech sector.
Clinical Trial Results: Discussions also highlight the positive Phase 1 results for REYOBIQ, shared at recent industry events, with users intrigued by its over 75% clinical benefit in treating central nervous system metastases. There’s a sense of anticipation about how these developments could shape the company’s future. Posts on X reflect curiosity about upcoming presentations at the Melanoma Research Foundation Brain Metastases Summit.
Financial Updates: Q3 financial results have sparked mixed reactions on X, with some noting a revenue dip and earnings miss, while others focus on the strengthened cash position. Concerns about potential Nasdaq delisting due to equity and bid price issues have also surfaced, adding a layer of caution to the conversation.
Note: This discussion summary was generated from an AI condensation of post data.
Plus Therapeutics Insider Trading Activity
Plus Therapeutics insiders have traded $PSTV stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:
- ROBERT P LENK purchased 110,000 shares for an estimated $53,779
- ANDREW JOHN HUGH MACINTYRE SIMS (Chief Financial Officer) purchased 20,000 shares for an estimated $10,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Plus Therapeutics Hedge Fund Activity
We have seen 10 institutional investors add shares of Plus Therapeutics stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALTIUM CAPITAL MANAGEMENT LLC added 918,914 shares (+inf%) to their portfolio in Q3 2025, for an estimated $628,261
- JANE STREET GROUP, LLC added 117,454 shares (+inf%) to their portfolio in Q2 2025, for an estimated $40,850
- HRT FINANCIAL LP removed 102,065 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $35,498
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 80,505 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $27,999
- UBS GROUP AG added 54,201 shares (+162.1%) to their portfolio in Q2 2025, for an estimated $18,851
- VIRTU FINANCIAL LLC removed 40,030 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,922
- GOLDMAN SACHS GROUP INC added 26,753 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,304
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Plus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- D. Boral Capital issued a "Buy" rating on 10/31/2025
- Ascendiant Capital issued a "Buy" rating on 10/06/2025
- Maxim Group issued a "Buy" rating on 08/18/2025
To track analyst ratings and price targets for Plus Therapeutics, check out Quiver Quantitative's $PSTV forecast page.
Plus Therapeutics Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Sean Lee from HC Wainwright & Co. set a target price of $2.0 on 11/03/2025
- Jason Kolbert from D. Boral Capital set a target price of $5.0 on 10/31/2025
- Edward Woo from Ascendiant Capital set a target price of $21.0 on 10/06/2025
- Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
